The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2022 | Comorbidities and treatment decisions in myelofibrosis

Name: Comorbidities and treatment decisions in myelofibrosis
Uploaded: 2022-06-01T00:00:00Z
Duration: 1 min 28 s
Description: John Mascarenhas, MD, The Mount Sinai Hospital, New York, NY, comments on competing comorbidities in patients with myelofibrosis (MF), highlighting the impact of these comorbidities on treatment decisions and emphasizing the role of a multidisciplinary team in such decisions. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

John Mascarenhas • 1 Jun 2022

EHA 2022

Myelofibrosis Myeloproliferative Neoplasms

John Mascarenhas, MD, The Mount Sinai Hospital, New York, NY, comments on competing comorbidities in patients with myelofibrosis (MF), highlighting the impact of these comorbidities on treatment decisions and emphasizing the role of a multidisciplinary team in such decisions. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding paid to Prof. Mascarenhas’ institution from Incyte, Novartis, Roche, BMS, Celgene, CTI Bio, Merck, PharmaEssentia, Abbvie, Kartos, Geron and consulting fees from Incyte, Celgene, BMS, Constellation, CTI Bio, Geron, Abbvie, Kartos, Novartis, Roche, Imago, Karyopharm, Galecto and PharmaEssentia.